{"transactions":[{"id":4618360,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:46.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":3386,"price":156.22,"value":528960.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":67297,"source":{"system":"sec-edgar","filing":"0001643653-26-000018","document":"wk-form4_1789506163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000018/wk-form4_1789506163.xml","form_type":"4"}},{"id":4618359,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:46.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":6275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":70683,"source":{"system":"sec-edgar","filing":"0001643653-26-000018","document":"wk-form4_1789506163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000018/wk-form4_1789506163.xml","form_type":"4"}},{"id":4615474,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":3194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.  These options were due to expire on February 6, 2027."}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":3194},"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":4615473,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":2154,"price":154.61,"value":333029.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":64408,"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":4615472,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":3194,"price":43.24,"value":138108.56,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":66562,"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":780530,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-13T20:15:41.000Z","date":"2026-05-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":50000,"derivative":{"exercise_price":0.95,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001643653-26-000014","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000164365326000014/ownership.xml","form_type":"4"}},{"id":902278,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":6365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."}],"balance_after":6365,"derivative":{"underlying":"Common Stock","underlying_shares":6365},"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902277,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":36287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":36287,"derivative":{"exercise_price":124.12,"expiration_date":"2036-02-13","underlying":"Common Stock","underlying_shares":36287},"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902276,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":2083,"derivative":{"underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902275,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":3924,"derivative":{"underlying":"Common Stock","underlying_shares":1961},"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902274,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":2005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award."}],"balance_after":6017,"derivative":{"underlying":"Common Stock","underlying_shares":2005},"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902273,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":8963,"price":124.12,"value":1112487.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":63190,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902272,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":16613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":72153,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902271,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1124,"price":124.12,"value":139510.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":55540,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902270,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56664,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902269,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1058,"price":124.12,"value":131318.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":54581,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902268,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1961,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55639,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902267,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1082,"price":123.1,"value":133194.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":53678,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":902266,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:46:55.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2005,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54760,"source":{"system":"sec-edgar","filing":"0001643653-26-000011","document":"wk-form4_1771368412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000011/wk-form4_1771368412.xml","form_type":"4"}},{"id":922929,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T23:21:32.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":2294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2294},"source":{"system":"sec-edgar","filing":"0001643653-26-000008","document":"wk-form4_1770160887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000008/wk-form4_1770160887.xml","form_type":"4"}},{"id":922928,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:21:32.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1292,"price":136.06,"value":175789.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":52755,"source":{"system":"sec-edgar","filing":"0001643653-26-000008","document":"wk-form4_1770160887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000008/wk-form4_1770160887.xml","form_type":"4"}},{"id":922927,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:21:32.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":2294,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54047,"source":{"system":"sec-edgar","filing":"0001643653-26-000008","document":"wk-form4_1770160887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000008/wk-form4_1770160887.xml","form_type":"4"}},{"id":937737,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2026-01-16T22:17:59.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":12830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":12830},"source":{"system":"sec-edgar","filing":"0001643653-26-000005","document":"wk-form4a_1768601876.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000005/wk-form4a_1768601876.xml","form_type":"4/A","original_submission_date":"2025-12-02"}},{"id":937736,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:17:59.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":12830,"price":35.99,"value":461751.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":57723,"source":{"system":"sec-edgar","filing":"0001643653-26-000005","document":"wk-form4a_1768601876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365326000005/wk-form4a_1768601876.xml","form_type":"4/A","original_submission_date":"2025-12-02"}},{"id":984210,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2025-12-02T22:21:44.000Z","date":"2025-11-28","kind":"exercise","planned":true,"acquired":false,"shares":5970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016.  These options were due to expire on February 5, 2026."}],"balance_after":6860,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":5970},"source":{"system":"sec-edgar","filing":"0001643653-25-000007","document":"wk-form4_1764714101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365325000007/wk-form4_1764714101.xml","form_type":"4"}},{"id":984209,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-02T22:21:44.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":5970,"price":151.7388,"value":905880.636,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":44893,"source":{"system":"sec-edgar","filing":"0001643653-25-000007","document":"wk-form4_1764714101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365325000007/wk-form4_1764714101.xml","form_type":"4"}},{"id":984208,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-02T22:21:44.000Z","date":"2025-11-28","kind":"exercise","planned":true,"acquired":true,"shares":5970,"price":35.99,"value":214860.3,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":50863,"source":{"system":"sec-edgar","filing":"0001643653-25-000007","document":"wk-form4_1764714101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000164365325000007/wk-form4_1764714101.xml","form_type":"4"}},{"id":1160841,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-02T21:18:49.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":50000,"derivative":{"exercise_price":3.34,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-062935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017025062935/ownership.xml","form_type":"4"}},{"id":1268278,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":1961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, and will vest as to 1,961 shares on February 13, 2026, 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, and will vest as to 1,961 shares on February 13, 2026, 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":5885,"derivative":{"underlying":"Common Stock","underlying_shares":1961},"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268277,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025,  and will vest as to 2,083 shares on February 13, 2026, and  2,083 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025,  and will vest as to 2,083 shares on February 13, 2026, and  2,083 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":4166,"derivative":{"underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268276,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":8022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":8022,"derivative":{"underlying":"Common Stock","underlying_shares":8022},"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268275,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":42805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":42805,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":42805},"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268274,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1056,"price":116.7091,"value":123244.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.86 to $117.78. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":44689,"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268273,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":1961,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45745,"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268272,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1098,"price":116.7421,"value":128182.8258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":43784,"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1268271,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:03:41.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44882,"source":{"system":"sec-edgar","filing":"0000914475-25-000057","document":"wk-form4_1739574214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000057/wk-form4_1739574214.xml","form_type":"4"}},{"id":1272419,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:44:22.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1860},"source":{"system":"sec-edgar","filing":"0000914475-25-000047","document":"wk-form4_1739403854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000047/wk-form4_1739403854.xml","form_type":"4"}},{"id":1272418,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:44:22.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":980,"price":118.3065,"value":115940.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42799,"source":{"system":"sec-edgar","filing":"0000914475-25-000047","document":"wk-form4_1739403854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000047/wk-form4_1739403854.xml","form_type":"4"}},{"id":1272417,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:44:22.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43779,"source":{"system":"sec-edgar","filing":"0000914475-25-000047","document":"wk-form4_1739403854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000047/wk-form4_1739403854.xml","form_type":"4"}},{"id":1285974,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:35:33.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":2294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":2294,"derivative":{"underlying":"Common Stock","underlying_shares":2294},"source":{"system":"sec-edgar","filing":"0000914475-25-000021","document":"wk-form4_1738708526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000021/wk-form4_1738708526.xml","form_type":"4"}},{"id":1285973,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:35:33.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":1207,"price":152.94,"value":184598.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 54 shares purchased on August 31, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":41919,"source":{"system":"sec-edgar","filing":"0000914475-25-000021","document":"wk-form4_1738708526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000021/wk-form4_1738708526.xml","form_type":"4"}},{"id":1285972,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:35:33.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":2294,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43126,"source":{"system":"sec-edgar","filing":"0000914475-25-000021","document":"wk-form4_1738708526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000021/wk-form4_1738708526.xml","form_type":"4"}},{"id":1333604,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T21:15:23.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning January 10, 2025, such that this option will be fully exercisable on December 10, 2027, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":100000,"derivative":{"exercise_price":3.29,"expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-135798","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024135798/ownership.xml","form_type":"4"}},{"id":1540464,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":false,"shares":12587,"price":81.05,"value":1020176.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019.  These options will expire ten years from the date of grant on February 07, 2029."}],"balance_after":0,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":12587},"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1540463,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":false,"shares":7231,"price":81.49,"value":589254.19,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.  These options will expire ten years from the date of grant on February 05, 2028."}],"balance_after":26292,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":7231},"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1540462,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":12587,"price":133.3646,"value":1678660.2202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.56 to $136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40778,"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1540461,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":true,"shares":12587,"price":81.05,"value":1020176.35,"ownership":{"direct":true},"balance_after":53365,"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1540460,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":7231,"price":133.3646,"value":964359.4226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.56 to $136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40778,"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1540459,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-04-17T21:19:53.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":true,"shares":7231,"price":81.49,"value":589254.19,"ownership":{"direct":true},"balance_after":48009,"source":{"system":"sec-edgar","filing":"0000914475-24-000111","document":"wk-form4_1713388780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000111/wk-form4_1713388780.xml","form_type":"4"}},{"id":1575537,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":69521,"price":81.05,"value":5634677.05,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019.  These options will expire ten years from the date of grant on February 07, 2029."}],"balance_after":12587,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":69521},"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1575536,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":5479,"price":79.02,"value":432950.58,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032."}],"balance_after":33881,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":5479},"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1575535,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":69521,"price":139.3789,"value":9689760.5069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40778,"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1575534,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":69521,"price":81.05,"value":5634677.05,"ownership":{"direct":true},"balance_after":110299,"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1575533,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":5479,"price":139.3789,"value":763656.9931,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40778,"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1575532,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-15T21:33:44.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":5479,"price":79.02,"value":432950.58,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 162 shares purchased on February 29, 2024  from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":46257,"source":{"system":"sec-edgar","filing":"0000914475-24-000096","document":"wk-form4_1710538413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000096/wk-form4_1710538413.xml","form_type":"4"}},{"id":1610890,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":21857,"price":79.02,"value":1727140.14,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032."}],"balance_after":39360,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":21857},"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1610889,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":53143,"price":43.24,"value":2297903.32,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.  These options will expire ten years from the date of grant on February 6, 2027."}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":53143},"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1610888,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":21857,"price":134.6881,"value":2943877.8017,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $133.82 to $136.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40616,"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1610887,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":21857,"price":79.02,"value":1727140.14,"ownership":{"direct":true},"balance_after":62473,"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1610886,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":53143,"price":134.6881,"value":7157729.6983,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $133.82 to $136.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40616,"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1610885,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:55:10.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":53143,"price":43.24,"value":2297903.32,"ownership":{"direct":true},"balance_after":93759,"source":{"system":"sec-edgar","filing":"0000914475-24-000082","document":"wk-form4_1709250893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000082/wk-form4_1709250893.xml","form_type":"4"}},{"id":1641713,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:29:53.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":7846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":7846,"derivative":{"underlying":"Common Stock","underlying_shares":7846},"source":{"system":"sec-edgar","filing":"0000914475-24-000068","document":"wk-form4_1708036181.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000068/wk-form4_1708036181.xml","form_type":"4"}},{"id":1641712,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:29:53.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":39426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":39426,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":39426},"source":{"system":"sec-edgar","filing":"0000914475-24-000068","document":"wk-form4_1708036181.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000068/wk-form4_1708036181.xml","form_type":"4"}},{"id":1641711,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:29:53.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":1098,"price":133.0149,"value":146050.3602,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,098 shares of common stock issued upon vesting of 2,083 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (985) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":40616,"source":{"system":"sec-edgar","filing":"0000914475-24-000068","document":"wk-form4_1708036181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000068/wk-form4_1708036181.xml","form_type":"4"}},{"id":1654152,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:15:11.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":980,"price":134.1925,"value":131508.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":39631,"source":{"system":"sec-edgar","filing":"0000914475-24-000044","document":"wk-form4_1707437696.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000044/wk-form4_1707437696.xml","form_type":"4"}},{"id":1654151,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:15:11.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":1280,"price":142.1172,"value":181910.016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $142.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":38751,"source":{"system":"sec-edgar","filing":"0000914475-24-000044","document":"wk-form4_1707437696.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000044/wk-form4_1707437696.xml","form_type":"4"}},{"id":1662741,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:05:25.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":1207,"price":140.7844,"value":169926.7708,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,207 shares of common stock issued upon vesting of 2,294 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.68 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 78 shares purchased on August 31, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":37601,"source":{"system":"sec-edgar","filing":"0000914475-24-000023","document":"wk-form4_1706918714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000023/wk-form4_1706918714.xml","form_type":"4"}},{"id":1799009,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-08-23T23:59:24.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":107.3975,"value":171836.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,600 shares of common stock issued upon vesting of 3,038 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,438) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36436,"source":{"system":"sec-edgar","filing":"0001209191-23-047128","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047128/doc4.xml","form_type":"4"}},{"id":2014195,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:06:10.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":8332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":8332,"derivative":{"underlying":"Common Stock","underlying_shares":8332},"source":{"system":"sec-edgar","filing":"0001209191-23-009881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009881/doc4.xml","form_type":"4"}},{"id":2014194,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:06:10.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":51782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":51782,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":51782},"source":{"system":"sec-edgar","filing":"0001209191-23-009881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009881/doc4.xml","form_type":"4"}},{"id":2026986,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:18:52.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":980,"price":104.1184,"value":102036.032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34381,"source":{"system":"sec-edgar","filing":"0001209191-23-007907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007907/doc4.xml","form_type":"4"}},{"id":2026985,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:18:52.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":15360,"price":102.4235,"value":1573224.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 15,360 shares of common stock issued upon vesting of 29,156 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (13,796) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.02 to $103.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33501,"source":{"system":"sec-edgar","filing":"0001209191-23-007907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007907/doc4.xml","form_type":"4"}},{"id":2026984,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:18:52.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":2030,"price":102.2872,"value":207643.016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.74 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19705,"source":{"system":"sec-edgar","filing":"0001209191-23-007907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007907/doc4.xml","form_type":"4"}},{"id":2026983,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:18:52.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":1280,"price":105.6256,"value":135200.768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.60 to $107.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":17879,"source":{"system":"sec-edgar","filing":"0001209191-23-007907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007907/doc4.xml","form_type":"4"}},{"id":2037150,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:00:01.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1207,"price":109.9505,"value":132710.2535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,207 shares of common stock issued upon vesting of 2,293 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,086) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16729,"source":{"system":"sec-edgar","filing":"0001209191-23-006259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006259/doc4.xml","form_type":"4"}},{"id":2057977,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2023-01-10T22:13:51.000Z","date":"2023-01-06","kind":"exercise","acquired":false,"shares":400,"price":43.24,"value":17296.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted February 06, 2017 and vested monthly over four years."}],"balance_after":53143,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001209191-23-002829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123002829/doc4.xml","form_type":"4"}},{"id":2057976,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-10T22:13:51.000Z","date":"2023-01-06","kind":"sale","acquired":false,"shares":400,"price":125,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-23-002829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123002829/doc4.xml","form_type":"4"}},{"id":2057975,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-10T22:13:51.000Z","date":"2023-01-06","kind":"exercise","acquired":true,"shares":400,"price":43.24,"value":17296.0,"ownership":{"direct":true},"balance_after":16043,"source":{"system":"sec-edgar","filing":"0001209191-23-002829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123002829/doc4.xml","form_type":"4"}},{"id":2100482,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":false,"shares":20063,"price":43.24,"value":867524.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 06, 2017 and vested monthly over four years."}],"balance_after":53543,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":20063},"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100481,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":false,"shares":7775,"price":35.99,"value":279822.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":7775},"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100480,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":false,"shares":22162,"price":41.78,"value":925928.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":41.78,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":22162},"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100479,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":20063,"price":125.9017,"value":2525965.8071,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $126.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100478,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":true,"shares":20063,"price":43.24,"value":867524.12,"ownership":{"direct":true},"balance_after":35706,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100477,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":7775,"price":125.9017,"value":978885.7175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $126.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100476,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":true,"shares":7775,"price":35.99,"value":279822.25,"ownership":{"direct":true},"balance_after":23418,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100475,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"sale","acquired":false,"shares":22162,"price":125.9017,"value":2790233.4754,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $126.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2100474,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:43:06.000Z","date":"2022-11-30","kind":"exercise","acquired":true,"shares":22162,"price":41.78,"value":925928.36,"ownership":{"direct":true},"balance_after":37805,"source":{"system":"sec-edgar","filing":"0001209191-22-059245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059245/doc4.xml","form_type":"4"}},{"id":2120414,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-10","kind":"exercise","acquired":false,"shares":100,"price":41.78,"value":4178.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016."}],"balance_after":22162,"derivative":{"exercise_price":41.78,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2120413,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-08","kind":"exercise","acquired":false,"shares":24593,"price":41.78,"value":1027495.54,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016."}],"balance_after":22262,"derivative":{"exercise_price":41.78,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":24593},"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2120412,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":100,"price":125.362,"value":12536.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.35 to $125.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2120411,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-10","kind":"exercise","acquired":true,"shares":100,"price":41.78,"value":4178.0,"ownership":{"direct":true},"balance_after":15743,"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2120410,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":24593,"price":125.3332,"value":3082319.3876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2120409,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-10T22:50:00.000Z","date":"2022-11-08","kind":"exercise","acquired":true,"shares":24593,"price":41.78,"value":1027495.54,"ownership":{"direct":true},"balance_after":40236,"source":{"system":"sec-edgar","filing":"0001209191-22-056437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122056437/doc4.xml","form_type":"4"}},{"id":2124799,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-03","kind":"exercise","acquired":false,"shares":8968,"price":41.78,"value":374683.04,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016."}],"balance_after":46855,"derivative":{"exercise_price":41.78,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":8968},"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2124798,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-02","kind":"exercise","acquired":false,"shares":400,"price":41.78,"value":16712.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016."}],"balance_after":55823,"derivative":{"exercise_price":41.78,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2124797,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":8968,"price":125.0204,"value":1121182.9472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2124796,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-03","kind":"exercise","acquired":true,"shares":8968,"price":41.78,"value":374683.04,"ownership":{"direct":true},"balance_after":24611,"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2124795,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":400,"price":125,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2124794,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-04T20:56:07.000Z","date":"2022-11-02","kind":"exercise","acquired":true,"shares":400,"price":41.78,"value":16712.0,"ownership":{"direct":true},"balance_after":16043,"source":{"system":"sec-edgar","filing":"0001209191-22-055817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055817/doc4.xml","form_type":"4"}},{"id":2135083,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-19T21:55:25.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":4960,"price":110.8229,"value":549681.584,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.54 to $111.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 265 shares purchased on February 28, 2022 and August 31, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001209191-22-054117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122054117/doc4.xml","form_type":"4"}}],"next_cursor":"2022-10-19T21:55:25.000000Z,2135083"}